echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The next ride for the medical tycoon.

    The next ride for the medical tycoon.

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 30, Dr. Liu Shigao said in a letter to all Fuhong Hanxuan that he would step down as executive director and chief executive officer of Fuhong Hanxuan, and that Mr. Zhang Wenjie, President of the Company, would take over the relevant position.
    , who founded Fuhong Hanxuan more than a decade ago, has witnessed the era of rapid change and development of China's pharmaceutical industry.
    to ride the fast train of the times, in recent years, the domestic also emerged a lot of like Fuhong Hanxuan, "the thorns, the way forward" pharmaceutical enterprises.
    the emergence of this situation can not be separated from the "talent" help, and with the acceleration of the development process of the industry, the flow of talent is more frequent.
    We've previously reported on the flow of talent in the pharmaceutical industry, from Wall Street investors to innovative pharmaceutical companies, from regulators like the FDA to pharmaceutical companies, from CRO giants to founders of start-ups.
    gathering is a fire, scattered with stars! At the same time that the times have created talents, talents are also making achievements.
    rubik's cube combed through the trend of high-end talent flow in the pharmaceutical industry, paying tribute to the predecessors who led the industry's continuous progress.
    to break the kettle sinking boat, the ambition of the unre unpaid vow to break the kettle sinking boat, to those who in the early years choose from multinational pharmaceutical companies, overseas scientific research institutions to return to the talent as a representative.
    such as Beida Pharmaceutical Ding Liming, micro-core biology Lu Xianping, Yasheng pharmaceutical Yang Dajun, the development of pharmaceutical children's friends, and the reputation of biology Xu Yaochang, Hongyun Huaning Jing Shuqian ... And so on, they have the dream of developing new drugs to return home to start a company, but in the face of high-risk, high-investment new drug research and development projects, they often face financing difficulties, sound policies, lack of talent problems at the beginning of the venture.
    shopping malls such as the battlefield, after hundreds of times, this group of entrepreneurs slowly fade the idealistic scientist feelings, adding a little bit of entrepreneurial temperament.
    is constantly changing, innovation has always been the soul and spiritual core of entrepreneurs.
    innovation, management innovation, product innovation, management innovation, product innovation, service innovation... Behind every "new" word lies courage, courage and responsibility.
    for example, Dr. Wu Jinxuan, founder of Goliath Pharmaceuticals, the first Biotech company to land on the Hong Kong Stock Exchange, was vice president of GlaxoSmithKline's antiviral drug discovery executive division in the United States before founding Goliath Pharmaceuticals.
    When he saw Gilead's hepatitis C drug sophosphobwe set a sky-high price of $1,000 a piece, Wu Jinxuan with a "let domestic hepatitis C patients can afford" the first heart to set up the goliath pharmaceutical industry, committed to the development of hepatitis C antiviral drugs.
    With the birth of a series of oral direct antiviral drugs to cure hepatitis C, goliath's original business model is no longer applicable, the secondary capital market share price performance is not satisfactory, but because of the emergence of such competitors as Goliath, so that multinational pharmaceutical companies in the drug price has made concessions.
    it is gratifying to note that the product line of Goliath Pharmaceuticals is now not limited to hepatitis C as an adaptive disease, but has expanded to other antiviral-related areas such as hepatitis B, AIDS, and the new crown.
    's stock code is 1672, which was originally intended to commemorate "Newton's observation in 1672 that apples fell from trees, triggered thinking, triggered the birth of the law of gravity, and ushered in a new era in physics."
    " as the first crab-eating Hong Kong Stock Exchange IPO company, Goli took the difficult first step, stepped on every pit, is reminding the those who later.
    choose to start a business may just be a footnote to the trajectory of these big men's lives, but completely different work scenarios require them to evolve different abilities.
    qualities do entrepreneurs need? Borrowing from Dr. Mei Jianming, founder of Deqi Pharmaceuticals, the answer is a holistic view, professionalism and business acumen, all of which are indispensable.
    business acumen is particularly important given the need to deal with investment, listing, regulatory agencies, market access, etc. in the entrepreneurial process.
    such as Li Ge of The Drug Ming Kant, Zhai Dechao of Xinda Creatures, Ou Leiqiang of Baiji Shenzhou... It's all about having a strong business acumen.
    In addition to active entrepreneurship, there are some are invited by capital, but these people also have a strong entrepreneurial spirit, such as Chen Li of Hualing Pharmaceuticals, Jiang Ningjun of Keystone Pharmaceuticals, Hong Zhi of Tengsheng Bo Pharmaceuticals, Cui Yusong of No Cheng Jianhua... The ambition of unre unpaid vows is their spiritual portrait.
    Cast Peach Li, became the left arm of many Biotech companies enjoy the dividends of the times of China's drug reform, the door of the capital market to them open arms, after a lot of hard-working innovation in the early years finally some eyebrows, even with a lot to put.
    when capital and technology are no longer the primary challenges facing entrepreneurs, the short board of commercial operations and a series of management loopholes need to be solved urgently, and the establishment of a management system suitable for the development of the company has become a top priority for entrepreneurs.
    , especially after the company's IPO goes into the public eye, it can't develop in a disorderly way like the initial stage, and a more standardized governance system needs to be established.
    also coincided with this period, a large number of multinational pharmaceutical companies or domestic traditional large pharmaceutical companies work background of senior executives to Biotech, accelerating the development of China's biopharmaceutical industry.
    's choice to join an innovative pharmaceutical company that hasn't yet grown into a big tree is certainly an expectation of future financial freedom, but similar growth backgrounds, relationships with people who have worked together, and mutually recognized business capabilities are also big factors in these executives' decisions.
    Luo Yongqing, former President of Gilead China, recently announced that he will join Tengsheng Bo Pharmaceuticals as President and General Manager of Greater China, with overall responsibility for the latter's Greater China business development and operations, and support the Company's business development in the United States.
    , a surgeon-turned-surgeon, has a background in multinational pharmaceutical companies such as Merca East, Novartis and Roche, and Hong Zhi, founder of Tengshengbo Pharmaceuticals, has been fighting for years in the field of antiviral drugs.
    to the common enemy, the cunning of the various viruses may also have prompted the two "antiviral" heroes to regret, and come together one of the reasons.
    Before Luo Yongqing, from the multinational pharmaceutical company's senior position in China to the position of innovative pharmaceutical companies, from Pfizer to Baiji Shenzhou, Dr. Wu Xiaobin, from Anjin to Fuhong Hanxuan, Mr. Zhang Wenjie, from AstraZeneta to Rending Pharmaceuticals, Dr. Liang Yi, from AstraZeneta to Pharmaceuticals Mingkang, Dr. Yang Qing, from Mercadon to Alice Pharmaceuticals, and so on.
    In addition, careers throughout the FDA, CDE and other regulatory agencies to the investment community now joinEd Rongchang Bio's Dr. He Ruyi, from Pharmaceutical Ming Bio to Junshi Bio's Dr. Wang Gang, from Lizhu Pharmaceuticals to Rongchang Bio's Dr. Fu Daotian has a similar career choice.
    Of course, there are some talents who have stayed in the original system, from this multinational pharmaceutical company to another multinational company, such as Novarma China's head of the corporate oncology division, Tian Yanping, who took over from Mu Yanping and joined Mercedon as head of China's oncology division.
    , who has worked for GE for 24 years, left to serve as an independent director of Sanofi.
    these big guys are not involved in the process of starting and growing a business, but with their rich experience, they have also become the left and right brains of current corporate decision makers.
    step back, going behind the scenes to direct for china's fast-growing pharmaceutical industry, it may be a little earlier to talk about success.
    but throughout the life cycle of global enterprises, corporate inheritance, intergenerational transmission is a topic that can not be bypassed.
    as the Book of Morals says: the work is done, the way of heaven is also.
    means that the cause has been completed, the strength to the extreme, then lead back, this is to follow the laws of nature.
    Whether Chinese or foreign or ancient and modern, any group and organization, to a certain level, on behalf of the team and organization of the first person, either authoritative, or back to the second line, to do behind-the-scenes control.
    January 16 this year, Hengrui Pharmaceuticals announced that Sun Weiyang will step down as chairman of the company, with General Manager Zhou Yunshu taking over as chairman of the company.
    For this personnel adjustment, Sun said that after that will be more time and energy into the company's strategic development planning, leading talent team building and to build a professional manager's long-term governance mechanism, and the specific operation of the enterprise to the professional manager team, the fundamental starting point is to make the enterprise eternal vitality, to build a hundred years of Hengrui.
    addition to Hengrui medicine, Yangzijiang's boss Xu Mirror people's next journey is also attracting much attention from the outside world.
    is it a father-in-law or a professional manager? Will Xu Mirror, who is entering his second year, let go? Another high-profile is China Biopharmaceuticals, the parent company of Zhengda Tianqing.
    China Biopharmaceuticals announced in August that founder Xie Wei would resign as CEO of the company and be succeeded by Li Yi, former chairman of JPMorgan Securities (China) Co., Ltd.
    , like Gan Li Pharmaceuticals, which has just landed in the capital markets this year, its chairman, Gan Zhongru, also announced shortly after the company's listing that he was retreating behind the scenes to do research and development, and arranged for "post-90" executives to step up to the stage.
    Chinese pharmaceutical companies as a whole are relatively young, but the generational succession of core management is still mostly a "mystery".
    face of "70 after the workaholic, 80 after refusing to work overtime, 90 after refusing to go to work..." The new normal, the older generation of management ideas can let young people pay? How corporate culture can take advantage of the wind and waves to adapt to the times, but also bring many challenges to managers, retreat behind the scenes decentralized successors as an option.
    few short decades of my career, everyone's path to development has been different.
    is a passer-by or a return, you and I have different choices, and the medical tycoons continue to write career legends in a variety of ways, no right or wrong, no questions about the West East.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.